Google Chrome
Safari
Firefox
Edge
Knowledge Center
Article / Jul 27, 2015
Hovione and Invion sign development agreement for first inhaled non-steroidal anti-inflammatory for asthma
Source:
Manufacturing Chemist, 27 July 2015
Portuguese API manufacturer Hovione has agreed with Invion to progress the development of inhaled INV104 (zafirlukast) as a potential new treatment for asthma.
Hovione and the Australian drug developer will collaborate to develop the proprietary novel technology – a dry powder formulation of the compound INV104 (zafirlukast) delivered by Hovione’s inhaler.
Related links
Also in the Knowledge Center
/ Dec 28, 2016
Electrophilic reagents for monohalomethylation, their preparation and their uses
Read more
Scientific Article
/ Dec 28, 2016
Continuous production of particles, micro- and/or nanoparticles, particulate amorphous solid dispersions, particulate co-crystals and pharmaceutical compns.
Read more
Scientific Article
/ Oct 23, 2016
Dry-Powder Inhalation Formulation: Balancing Performance and Manufacturability
Read more
Scientific Article